OTX 008

Drug Profile

OTX 008

Alternative Names: OTX-008; PTX-008

Latest Information Update: 20 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PepTx
  • Developer OncoEthix
  • Class Antineoplastics; Calixarenes; Small molecules
  • Mechanism of Action Galectin-1-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Dec 2014 OncoEthix has been acquired by Merck & Co
  • 22 Oct 2013 In vitro pharmacodynamics data in Cancer presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)
  • 01 Feb 2012 Phase-I clinical trials in Solid tumours (second-line therapy or greater) in Belgium (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top